Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) Transcript

Jun 23, 2020 / 07:00PM GMT
George Farmer
BMO Capital Markets Equity Research - Analyst

Hi. Good afternoon. I'm George Farmer, senior biotechnology analyst at BMO Capital Markets. Thank you for attending our afternoon session today, our Virtual BMO Healthcare Conference.

With me today, I'm very pleased to have Stéphane Bancel, the Chief Executive Officer of Moderna, to speak with us in a fireside chat format. We'll talk about Moderna's very exciting RNA therapeutic vaccine pipeline with, I think, most focus on 1273, the coronavirus vaccine that is currently in Phase II development, and as we all understand, is about to begin Phase III. So thank you, Stéphane, for being here.

StÃ;phane Bancel
Moderna, Inc. - CEO & Director

© -

Thank you for having me, George.

Questions & Answers

George Farmer
BMO Capital Markets Equity Research - Analyst

Yes. Very good. So perhaps you can just give us an overview, for maybe people who aren't entirely familiar with what Moderna is doing, about the overall Moderna

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot